InflaRx N.V. (IFRX) vs Pyxis Oncology (PYXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
InflaRx N.V. (IFRX) has outperformed Pyxis Oncology (PYXS) over the past year, gaining 13.0% versus a loss of 21.2%. Over five years, IFRX leads with a -36.8% price change compared with -82.9% for PYXS. Pyxis Oncology is the larger company by market cap ($237.7 million vs $225.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IFRX | PYXS |
|---|---|---|
| Share price | $1.53 | $1.99 |
| Market cap | $225.47M | $237.72M |
| 1-day change | -1.92% | -1.00% |
| YTD return | +54.46% | +74.78% |
| 1-year return | +13.04% | -21.18% |
| 5-year return | -36.84% | -82.92% |
| EPS (TTM) | $-0.58 | $-1.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.95 | $5.55 |
| 52-week low | $0.798 | $1.03 |
| Distance from 52-week high | -48.12% | -64.14% |
| Analyst consensus | none | none |
| Avg. price target upside | +400.65% | +335.68% |
| Average volume | 794.10K | 1.25M |
| Shares outstanding | 147.37M | 119.46M |
| Employees | 65 | 56 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IFRX has outperformed PYXS by 34.2 percentage points over the past year.
About InflaRx N.V.
IFRX stock →InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
About Pyxis Oncology
PYXS stock →Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
IFRX vs PYXS FAQ
Which is bigger, InflaRx N.V. or Pyxis Oncology?
Pyxis Oncology (PYXS) is larger, with a market capitalization of $237.72M compared with $225.47M for InflaRx N.V. (IFRX).
Which stock has performed better over the past year, IFRX or PYXS?
IFRX returned +13.04% over the past 12 months, compared with -21.18% for PYXS (price return, excluding dividends). Past performance does not predict future results.
Are InflaRx N.V. and Pyxis Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.